Navigation Links
Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
Date:5/15/2008

could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligati
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... AMSTERDAM, August 17 SynCo ... Inc. today,announced a strategic partnership to produce Versartis, lead ... to treat type 2 diabetes,Under the agreement, SynCo will ... optimize the manufacturing process to,increase yields for the forthcoming ...
... /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ) ("China-Biotics", "the ... marketing and,distribution of probiotics products, today announced its financial results ... 30, 2009. , , First Quarter 2010 ... to $15.4 million, -- Gross profit rose ...
... water for granted, that ordinary tap water could become deadly ... School of Physics and Astronomy. To combat the threat ... the physicist has developed a new system to monitor the ... time. Modifying special fibers developed in his Tel ...
Cached Biology Technology:SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 11Monitoring water through a snake's eyes 2Monitoring water through a snake's eyes 3
(Date:7/9/2014)... of studies suggest that children delivered by Caesarean section have ... But it is still unknown why this is the case ... the Faculty of Health and Medical Sciences therefore decided to ... immune system in a study of newborn mouse pups. ... Caesarean section had developed a lower number of cells that ...
(Date:7/9/2014)... switch out one gene for another in a line ... fiction to reality within this decade. As with any ... of fixing disease-causing genes in humans, for example--as well ... put one of those concerns to rest: using gene-editing ... of mutations in the cells. The new results were ...
(Date:7/9/2014)... Ind. - Regulated deer hunts in Indiana state parks ... decades of damage caused by overabundant populations of white-tailed ... led by Michael Jenkins, associate professor of forest ecology, ... policy of organizing hunts in state parks has successfully ... wildflowers rendered scarce by browsing deer. , Jenkins ...
Breaking Biology News(10 mins):Mouse study: Natural birth may strengthen the immune system 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2
... 2013 AT&T * and NEC Corporation of ... workhorse among ruggedized 4G LTE smartphones , the ... equipped with AT&T Enhanced Push-to-Talk (EPTT)**, NEC ... is aimed at breaking productivity barriers to keep workforces ...
... anabolic agent for tissue-building and energy storage, promoting the ... inhibiting their breakdown and release into the circulatory system. ... entry into muscle tissue, where the glucose is metabolized ... exist in understanding the precise molecular mechanisms by which ...
... YORK , June 19, 2013  New York College of ... States Patent and Trademark Office for detecting biometric changes through ... have been injured, attacked or killed. This patent ... Agreements of New York College of Health Professions. ...
Cached Biology News:AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 2AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 3AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 4AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 5Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4
Rb anti-Occludin (C-term GST)...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: